DDInter1824 DDInter1376
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. It was later approved by Health Canada on 30 April 2010. After being investigated to treat severely ill patients with COVID-19,[A193278,L12837,L12843] tocilizumab was approved by the European Commission in December 2021 to treat COVID-19 in adults receiving systemic corticosteroids and supplemental oxygen or mechanical ventilation. Subsequently, it was granted approval by Health Canada and the FDA in October and December 2022, respectively. Tociliz
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Tocilizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Tocilizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Tocilizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isradipine
Tocilizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dienogest
Tocilizumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tocilizumab {u} may lead to a major life threatening interaction when taken with {v} Canakinumab
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Isradipine
Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Dienogest
Tocilizumab may lead to a major life threatening interaction when taken with Fingolimod
Tocilizumab may lead to a major life threatening interaction when taken with Canakinumab